Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the […]

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions

Lead Alzheimer’s candidate shows clear biological effects and antidepressant potential

Deal covers up to five candidates including SB36 as company expands global pipeline

Study to explore mechanism behind novel oral therapy for muscle‑sparing weight loss

Financing and global licensing deal to accelerate phase 2b development of AP306

Collaboration aims to streamline and scale next‑generation Treg therapy production

Study to assess oral therapy for patients with inadequate response to TNF inhibitors

Phase 3 trial delivers significant skin clearance and symptom improvement

Regulator authorises deuruxolitinib for adults with extensive hair loss